1. Home
  2. IMCR vs VSAT Comparison

IMCR vs VSAT Comparison

Compare IMCR & VSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$36.16

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo ViaSat Inc.

VSAT

ViaSat Inc.

N/A

Current Price

$76.59

Market Cap

9.6B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
IMCR
VSAT
Founded
2008
1986
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Radio And Television Broadcasting And Communications Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
9.6B
IPO Year
2016
1996

Fundamental Metrics

Financial Performance
Metric
IMCR
VSAT
Price
$36.16
$76.59
Analyst Decision
Buy
Strong Buy
Analyst Count
10
6
Target Price
$66.33
$59.80
AVG Volume (30 Days)
413.9K
2.0M
Earning Date
05-07-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
30.39
94.42
EPS
0.23
N/A
Revenue
$249,428,000.00
N/A
Revenue This Year
$14.57
$5.32
Revenue Next Year
$8.21
$3.57
P/E Ratio
$152.39
N/A
Revenue Growth
43.05
N/A
52 Week Low
$27.56
$25.50
52 Week High
$40.71
$93.03

Technical Indicators

Market Signals
Indicator
IMCR
VSAT
Relative Strength Index (RSI) 64.48 49.91
Support Level $35.46 $67.49
Resistance Level $37.25 $90.40
Average True Range (ATR) 1.32 5.60
MACD 0.05 -0.29
Stochastic Oscillator 87.76 38.01

Price Performance

Historical Comparison
IMCR
VSAT

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About VSAT ViaSat Inc.

Viasat Inc an world-wide provider of communications technologies and services, focused on making connectivity accessible, available and secure for current and future customers world-wide. The company has two reportable segments: communication services and defense and advanced technologies. It generates majority of revenue from communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers. It has presence in United States and Outside United States. The company generates majority of revenue from United States. Its products are Antennas, Terminals & radios, Modems, Semiconductors, Cybersecurity, Software & services, Home internet.

Share on Social Networks: